FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 THE AVONEX CHANNEL
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week
March 2005   
April 2005   
June 2005   
July 2005   
August 2005   
September 2005   
October 2005   
November 2005   
May 2006   
June 2006   
July 2006   
October 2006   
April 2010   
May 2013   
June 2013   
July 2013   
August 2013   
July 2014   
November 2014   
January 2015   
February 2015   
April 2015   
July 2015   
January 2016   
March 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

1200 People With Relapsing MS Needed For RPC1063, Avonex Clinical Trials























Clinical investigators worldwide are beginning to recruit 1,200 patients with relapsing multiple sclerosis for a study assessing the effectiveness of two different doses of RPC1063 (Receptos, Inc.), an experimental oral therapy, and Avonex® (interferon beta-1a, Biogen Inc.) in order to reduce relapse rate in patients. This study, called the Sunbeam Study, is being funded by Receptos, Inc.

RPC1063 is a selective sphingosine 1-phosphate receptor modulator that acts like Gilenya® (fingolimod, Novartis International AG) and was designed to retain specific white blood cells in the lymph nodes of the body in order to keep them from entering the central nervous system. MRI lesions in 258 participants suffering from relapsing MS previously enrolled in a phase 2 trial were reduced by 86 percent in two RPC1063 study arms in comparison to placebo. Most frequent adverse events in the previous study were headache, respiratory infections and urinary tract infections. No notable lung, heart, eye problems or cancers were reported.

Participants in the study will be given active treatment with Avonex or the experimental therapy and will be randomly selected to be part of one of the three groups of 400 patients taking oral RPC1063 (5 mg), RPC1063 (1 mg) or Avonex.

The primary outcome being assessed by the study is relapse rate at month 12, and secondary outcomes include MRI scans, alterations in the MS Functional Composite (a measure of disease progression), time to sustained disease progression, brain tissue volume loss, visual function and quality of life.

Prospective participants should be relapsing MS patients between the ages of 18 and 55 and with an RRMS diagnosis. More details on inclusion/exclusion criteria are available here https://www.sunbeamstudy.com.

Roche recently announced encouraging results on its investigational medicineocrelizumab as a therapy for patients with relapsing multiple sclerosis, which includes either RRMS or SPMS with relapses. Ocrelizumab was evaluated in two pivotal studies (OPERA I and OPERA II), where it was compared to interferon (IFN) beta-1a (Rebif®), the standard-of-care therapy in patients with relapsing MS.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length
Click here to read original article

Labels: